Sign In
Buy DTCFF
$0.299
+0.0178 (+6.31%)
At Close: Jul 31, 2026
Defence Therapeutics (OTCMKTS:DTCFF) Shares Down 5.9% – Here’s What Happened
02:07am, Saturday, 27'th Dec 2025
Defence Therapeutics Inc. (OTCMKTS:DTCFF - Get Free Report)'s stock price dropped 5.9% during mid-day trading on Friday. The company traded as low as $0.5647 and last traded at $0.5647. Approximately
Defence Therapeutics to Present at the Life Sciences Virtual Investor Forum December 11th
08:35am, Thursday, 11'th Dec 2025
Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com Company invites individual and institutional investors, as
Defence Therapeutics Announces AGM Results and Provides Corporate Updates
04:30pm, Wednesday, 10'th Dec 2025
Montreal, Quebec--(Newsfile Corp. - December 10, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a biotechnology company advancing a proprietary in
Montreal, Quebec--(Newsfile Corp. - December 4, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a biotechnology company advancing a proprietary i
Defence Therapeutics Announces Convertible Debenture Conversion
06:02pm, Friday, 21'st Nov 2025
Montreal, Quebec--(Newsfile Corp. - November 21, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company pioneering next-g
Defence Therapeutics to Build ADC Drug Delivery Powerhouse Using Its Proprietary Accum Technology
03:15am, Wednesday, 19'th Nov 2025
Montreal, Quebec--(Newsfile Corp. - November 19, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company pioneering next-
Montreal, Quebec--(Newsfile Corp. - November 6, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company pioneering next-gen
Defence Therapeutics Demonstrates Strong Preclinical in Vivo Efficacy Results Evaluating Accum-Kadcyla in Breast Cancer Models
03:15am, Tuesday, 04'th Nov 2025
Montreal, Quebec--(Newsfile Corp. - November 4, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company specialized in drug
Montreal, Quebec--(Newsfile Corp. - October 23, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company specialized in drug
Defence Therapeutics to Attend CPHI Worldwide in Frankfurt, October 28-30, 2025
03:15am, Monday, 06'th Oct 2025
Montreal, Quebec--(Newsfile Corp. - October 6, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company specialized in drug
Defence Therapeutics Appoints Dr. Mark Lambermon as Head of Quality and Operations
03:15am, Thursday, 02'nd Oct 2025
Montreal, Quebec--(Newsfile Corp. - October 2, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company specialized in drug
Defence's Director, Strategy & Business Advisor Dr. Amie Phinney Discusses the Accum Platform on Money Talk Radio with Ellis Martin
09:15am, Tuesday, 23'rd Sep 2025
Montreal, Quebec--(Newsfile Corp. - September 23, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company specialized in dr
Defence Therapeutics Appoints Dr. Amie Phinney as Director
03:15am, Tuesday, 16'th Sep 2025
Montreal, Quebec--(Newsfile Corp. - September 16, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company specialized in d
Defence Therapeutics Completes Fully Subscribed Debenture Units Financing of $2,000,000
04:30pm, Monday, 15'th Sep 2025
Montreal, Quebec--(Newsfile Corp. - September 15, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specialized in
Defence Therapeutics Engages Dr. Amie Phinney as Strategy & Business Advisor to Guide Next Phase of Growth
03:15am, Tuesday, 02'nd Sep 2025
Montreal, Quebec--(Newsfile Corp. - September 2, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specialized in dru
